# Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

> **NCT07205731** · PHASE2 · RECRUITING · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 95 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1

## Key facts

- **NCT ID:** NCT07205731
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2029-10
- **Final completion:** 2030-10
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205731, "Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07205731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*